Catalyst Biosciences Reports First Quarter 2017 Financial Results and Provides Corporate Update

SOUTH SAN FRANCISCO, Calif., May 11, 2017 (GLOBE NEWSWIRE) — Catalyst Biosciences, Inc. (CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology indications, today announced financial results for the first quarter ended March 31, 2017.